About Us

Founded in 2008, Indel Therapeutics is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of new antibiotics to address the global health crisis caused by antibiotic resistance.

The Company has a growing pipeline of novel small-molecule antibiotic drug discovery programs that aim to cure serious, life-threatening infections.  These programs are based on Indel’s paradigm-changing antimicrobial drug discovery platform, a patented technology that has opened a rich, new area of drug targets for the treatment of bacterial and parasitic infections and, potentially, fungal and viral infections.

The Indel platform technology allows it to identify and target discrete amino acid insertion/ deletion differences (“indels”) between essential homologous proteins that are evolutionarily conserved across the pathogen (bacteria) and humans. Based on these structural differences, the Company can selectively target the pathogen protein with small molecules without hitting the human counterpart protein, thereby reducing toxicity concerns.

Indel targets are considered one of the first new major classes of antimicrobial targets identified in decades and provide a way to attack drug-resistant microbes by inhibiting indel-differentiated targets with novel drugs.

Indel’s lead program focuses on the treatment of methicillin resistant Staphylococcus aureus (MRSA), a multidrug resistant super bug responsible for a growing proportion of hospital-acquired and community-acquired infections that result in significant morbidity and mortality. The Company is also working on a number of indel-related Gram Negative antibiotic drug discovery programs.

With the emergence and growth of antibiotic resistance, serious infections are becoming more difficult, if not impossible to treat, causing hundreds of thousands of deaths worldwide each year. This has created an urgent need for new antibiotics with novel mechanisms of action to fight the growing array of multidrug-resistant pathogens.